FDA Recall D-0582-2025

Westminster Pharmaceuticals LLC · Nashville, TN

Class II Ongoing 281 days on record

Moderate impact — Class II recall — temporary or medically reversible adverse health consequence possible; remote probability of serious adverse health consequence.

Product

Metoprolol Tartrate Tablets, USP, 100 mg, 1000 Tablets, Rx Only, Manufactured by: Renata PLC (General Plant -2), Noyapara, Bhawal Mirzapur, Rajendrapur, Gazipur, 1700 Bangladesh, Distributed by: Westminster Pharmaceuticals, LLC, Nashville, TN 37217, NDC 69367-355-10

Lot / code: Batch # R56240011, Exp Date: 2/28/26; Batch # R56240021, R56240031, Exp Date: 3/31/26; Batch # R56240041, R56240051, R56240061, Exp Date: 4/30/26; Batch # R56240071, Exp Date: 7/31/26

Quantity: 4,456 1000-count bottles

Reason for recall

CGMP Deviations: Presence of a nitrosamine, N-nitroso-metoprolol above the established Acceptable Daily Intake (ADI) level.

Recall record

Recall number: D-0582-2025
Classification: Class II
Status: Ongoing
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Distribution: Nationwide in the USA.
Recall initiated: 2025-08-06
Classified by FDA Center: 2025-08-12
FDA published: 2025-08-20
Recalling firm: Westminster Pharmaceuticals LLC
Firm location: Nashville, TN

Drug identification

Brand name(s): METOPROLOL TARTRATE
Generic name(s): METOPROLOL TARTRATE
Manufacturer(s): Westminster Pharmaceuticals, LLC
NDC(s): 69367-354, 69367-355
Route(s): ORAL

Operational response

Class II recalls indicate possible temporary or reversible health consequences. Remove affected lots from active dispensing. Segregate inventory. Check the firm’s recall notification for guidance on patient outreach.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls